Evidence map›Paper›PMID 35995421›Full record

ArticleAnalytical chemistry2022

Proteogenomics and Differential Ion Mobility Enable the Exploration of the Mutational Landscape in Colon Cancer Cells.

Zhaoguan Wu, Éric Bonneil, Michael Belford, Cornelia Boeser, Maria Virginia Ruiz Cuevas, Sébastien Lemieux, Jean-Jacques Dunyach, Pierre Thibault

Abstract read
In one paragraph

Article in Analytical chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Intracellular pH regulates ubiquitin-mediated degradation of the MAP kinase ERK3.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhaoguan WuInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Quebec 514 343-6910, Canada.
Éric BonneilInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Quebec 514 343-6910, Canada.ORCID 0000-0002-4039-3131
Michael BelfordThermoFisher Scientific, San Jose, California 95134, United States.
Cornelia BoeserThermoFisher Scientific, San Jose, California 95134, United States.
Maria Virginia Ruiz CuevasInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Quebec 514 343-6910, Canada.
Sébastien LemieuxInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Quebec 514 343-6910, Canada.
Jean-Jacques DunyachThermoFisher Scientific, San Jose, California 95134, United States.
Pierre ThibaultInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Quebec 514 343-6910, Canada.ORCID 0000-0001-5993-0331

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The sensitivity and depth of proteomic analyses are limited by isobaric ions and interferences that preclude the identification of low abundance peptides. Extensive sample fractionation is often required to extend proteome coverage when sample amount is not a limitation. Ion mobility devices provide a viable alternate approach to resolve confounding ions and improve peak capacity and mass spectrometry (MS) sensitivity. Here, we report the integration of differential ion mobility with segmented ion fractionation (SIFT) to enhance the comprehensiveness of proteomic analyses. The combination of differential ion mobility and SIFT, where narrow windows of ∼

Indexed as

Colonic NeoplasmsProteogenomicsChromatography, LiquidHumansIonsProteomeProteomicsTandem Mass SpectrometryIonsProteome

Identifiers

PMID35995421
PMCPMC9454824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.